Efficacy and Safety of Mycophenolate Mofetil Monotherapy in Liver Transplant Patients With Renal Failure Induced by Calcineurin Inhibitors

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 2985-2987

  Barrera Pulido, L ^a   Alamo Martinez J M ^a   Pareja Ciuro F ^a   Gomez Bravo M A ^a   Serrano Diez Canedo J ^a   Bernal Bellido, C ^a   Suarez Artacho G ^a   Garcia Gonzalez I ^a   Pascasio Acevedo, J M ^a   Bernardos Rodriguez A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; RECIPIENT; TREATMENT DURATION; TREATMENT OUTCOME;

CALCINEURIN; CREATININE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; LEUKOCYTE COUNT; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SAFETY; TIME FACTORS; TREATMENT FAILURE; URIC ACID;

EID: 55749086805     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.017     Document Type: Article

References (9)

1. Danovitch G.M. Immunosuppressant-induced metabolic toxicities. Transplant Rev 14 (2000) 65
2. Gonwa T.A., Mai M.L., Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy and risk of development and treatment. Transplantation 12 (2001) 1934
3. Bilbao I., Castells L., Rojas L., et al. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 6 (2006) 1977
4. Beckebaum S., Cicinnati C.G., Klein E., et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 36 (2004) 2671
5. Wu J.C. Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Disc Design 2 (1994) 185
6. Hodge E.E., Reich D.J., Clavien P.A., et al. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. Transplant Proc 34 (2002) 1546
7. Moreno-Planas J.M., Martínez V., Cuervas-Mons, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4 (2004) 1650
8. Fairbanks K., and Thuluvath J. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 10 (2004) 1189
9. Schlitt H.J., Barkmann A., Boker K.H., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 357 (2001) 587